In the fight against pediatric obesity, a growing number of U.S. adolescents are seeking help from Novo Nordisk’s weight-loss medication, Wegovy. Exclusive data shared with Reuters sheds light on this trend, indicating a shift in the approach to addressing record rates of obesity among youth.
Surge in Wegovy Usage
In the first 10 months of 2023, 1,268 adolescents aged 12 to 17 initiated treatment with Wegovy, compared to just 25 in 2022. This significant increase follows the medication’s approval for adolescent use in December 2022, and subsequent endorsement by the American Academy of Pediatrics.
Similar Uptick in Medicaid Data
Data from five states, including Michigan and Minnesota, reflect a similar rise in Wegovy prescriptions, with at least 464 children receiving the medication since January 2022. However, this does not account for prescriptions obtained without insurance coverage or off-label use of similar treatments.
Addressing Pediatric Obesity
Despite the growing acceptance of Wegovy, pediatric obesity remains a significant public health concern, affecting nearly 20% of U.S. children. Obesity is linked to serious health conditions such as diabetes, heart disease, and cancer.
Family Decisions and Success Stories
Some families, initially hesitant about Wegovy due to concerns about side effects and long-term risks, have witnessed remarkable results. Billy Small III, after starting Wegovy in March 2023, has lost about 90 pounds, improving his quality of life significantly.
Future Prospects
Both Novo Nordisk and Eli Lilly are exploring weight-loss drugs for younger children, recognizing the need for effective interventions beyond traditional methods like diet and exercise.
Global Impact
The U.S. is among a few countries testing weight-loss drugs in youth, with potential lessons for global health strategies. Last year, Wegovy received approvals for youth use in several countries, including Germany and the UK.
Challenges and Caution
Wegovy’s high cost and potential for weight regain raise concerns, highlighting the need for further research and comprehensive approaches to pediatric obesity. Some experts advocate for intensive counseling and behavioural therapy over medication.
Conclusion
As adolescents turn to Wegovy in increasing numbers, it underscores the urgency of addressing pediatric obesity. While medications like Wegovy offer hope, a holistic approach that considers individual needs and potential risks is essential in promoting long-term health and well-being among youth.
